Cargando…
New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan
Tyrosyl-DNA-phosphodiesterase 1 (TDP1) is an important enzyme in the DNA repair system. The ability of the enzyme to repair DNA damage induced by a topoisomerase 1 poison such as the anticancer drug topotecan makes TDP1 a promising target for complex antitumor therapy. In this work, a set of new 5-h...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253161/ https://www.ncbi.nlm.nih.gov/pubmed/37298106 http://dx.doi.org/10.3390/ijms24119155 |
_version_ | 1785056341263384576 |
---|---|
author | Khomenko, Tatyana M. Zakharenko, Alexandra L. Kornienko, Tatyana E. Chepanova, Arina A. Dyrkheeva, Nadezhda S. Artemova, Anastasia O. Korchagina, Dina V. Achara, Chigozie Curtis, Anthony Reynisson, Jóhannes Volcho, Konstantin P. Salakhutdinov, Nariman F. Lavrik, Olga I. |
author_facet | Khomenko, Tatyana M. Zakharenko, Alexandra L. Kornienko, Tatyana E. Chepanova, Arina A. Dyrkheeva, Nadezhda S. Artemova, Anastasia O. Korchagina, Dina V. Achara, Chigozie Curtis, Anthony Reynisson, Jóhannes Volcho, Konstantin P. Salakhutdinov, Nariman F. Lavrik, Olga I. |
author_sort | Khomenko, Tatyana M. |
collection | PubMed |
description | Tyrosyl-DNA-phosphodiesterase 1 (TDP1) is an important enzyme in the DNA repair system. The ability of the enzyme to repair DNA damage induced by a topoisomerase 1 poison such as the anticancer drug topotecan makes TDP1 a promising target for complex antitumor therapy. In this work, a set of new 5-hydroxycoumarin derivatives containing monoterpene moieties was synthesized. It was shown that most of the conjugates synthesized demonstrated high inhibitory properties against TDP1 with an IC(50) in low micromolar or nanomolar ranges. Geraniol derivative 33a was the most potent inhibitor with IC(50) 130 nM. Docking the ligands to TDP1 predicted a good fit with the catalytic pocket blocking access to it. The conjugates used in non-toxic concentration increased cytotoxicity of topotecan against HeLa cancer cell line but not against conditionally normal HEK 293A cells. Thus, a new structural series of TDP1 inhibitors, which are able to sensitize cancer cells to the topotecan cytotoxic effect has been discovered. |
format | Online Article Text |
id | pubmed-10253161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102531612023-06-10 New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan Khomenko, Tatyana M. Zakharenko, Alexandra L. Kornienko, Tatyana E. Chepanova, Arina A. Dyrkheeva, Nadezhda S. Artemova, Anastasia O. Korchagina, Dina V. Achara, Chigozie Curtis, Anthony Reynisson, Jóhannes Volcho, Konstantin P. Salakhutdinov, Nariman F. Lavrik, Olga I. Int J Mol Sci Article Tyrosyl-DNA-phosphodiesterase 1 (TDP1) is an important enzyme in the DNA repair system. The ability of the enzyme to repair DNA damage induced by a topoisomerase 1 poison such as the anticancer drug topotecan makes TDP1 a promising target for complex antitumor therapy. In this work, a set of new 5-hydroxycoumarin derivatives containing monoterpene moieties was synthesized. It was shown that most of the conjugates synthesized demonstrated high inhibitory properties against TDP1 with an IC(50) in low micromolar or nanomolar ranges. Geraniol derivative 33a was the most potent inhibitor with IC(50) 130 nM. Docking the ligands to TDP1 predicted a good fit with the catalytic pocket blocking access to it. The conjugates used in non-toxic concentration increased cytotoxicity of topotecan against HeLa cancer cell line but not against conditionally normal HEK 293A cells. Thus, a new structural series of TDP1 inhibitors, which are able to sensitize cancer cells to the topotecan cytotoxic effect has been discovered. MDPI 2023-05-23 /pmc/articles/PMC10253161/ /pubmed/37298106 http://dx.doi.org/10.3390/ijms24119155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khomenko, Tatyana M. Zakharenko, Alexandra L. Kornienko, Tatyana E. Chepanova, Arina A. Dyrkheeva, Nadezhda S. Artemova, Anastasia O. Korchagina, Dina V. Achara, Chigozie Curtis, Anthony Reynisson, Jóhannes Volcho, Konstantin P. Salakhutdinov, Nariman F. Lavrik, Olga I. New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan |
title | New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan |
title_full | New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan |
title_fullStr | New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan |
title_full_unstemmed | New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan |
title_short | New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan |
title_sort | new 5-hydroxycoumarin-based tyrosyl-dna phosphodiesterase i inhibitors sensitize tumor cell line to topotecan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253161/ https://www.ncbi.nlm.nih.gov/pubmed/37298106 http://dx.doi.org/10.3390/ijms24119155 |
work_keys_str_mv | AT khomenkotatyanam new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT zakharenkoalexandral new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT kornienkotatyanae new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT chepanovaarinaa new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT dyrkheevanadezhdas new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT artemovaanastasiao new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT korchaginadinav new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT acharachigozie new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT curtisanthony new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT reynissonjohannes new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT volchokonstantinp new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT salakhutdinovnarimanf new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan AT lavrikolgai new5hydroxycoumarinbasedtyrosyldnaphosphodiesteraseiinhibitorssensitizetumorcelllinetotopotecan |